RespireRx Pharmaceuticals Inc. to Participate in Upcoming January Virtual Investor Conferences
From our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.
- From our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.
- Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
- Epilepsy is a chronic and highly prevalent neurological disorder that affects millions of people world-wide.
- We believe that the medical and patient community are in clear agreement that there is desperate need for improved antiepileptic drugs.